D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock. D. Boral Capital's price target suggests a potential upside of 199.40% from the stock's previous close.

A number of other analysts also recently weighed in on ANIX. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, March 25th. Maxim Group started coverage on shares of Anixa Biosciences in a research note on Friday, March 21st. They issued a "buy" rating and a $10.00 target price for the company. Finally, Wall Street Zen raised shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $9.00.

Anixa Biosciences Trading Down 7.2%

ANIX stock traded down $0.26 during trading on Tuesday, hitting $3.34. 168,084 shares of the stock traded hands, compared to its average volume of 100,469. The stock has a market cap of $107.58 million, a price-to-earnings ratio of -8.56 and a beta of 0.34. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The company has a 50 day simple moving average of $2.75 and a 200 day simple moving average of $2.80.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. As a group, analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar bought 10,000 shares of the firm's stock in a transaction on Wednesday, June 4th. The shares were purchased at an average cost of $2.85 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now directly owns 569,925 shares in the company, valued at $1,624,286.25. This represents a 1.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 25.30% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANIX. Millennium Management LLC acquired a new stake in Anixa Biosciences in the fourth quarter valued at $26,000. Private Advisor Group LLC acquired a new stake in shares of Anixa Biosciences in the first quarter valued at about $35,000. Renaissance Technologies LLC raised its position in shares of Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after acquiring an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. bought a new position in shares of Anixa Biosciences during the fourth quarter worth about $54,000. Finally, Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the fourth quarter worth approximately $67,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.